Kathy Francissen Ph.D.

Executive Director, Biologics Development, CMC Regulatory, Genentech

Kathleen Francissen, Ph.D. is currently focused on the development of individualized neoantigen-specific immunotherapies at Genentech/Roche. She has over 20 years of experience in the biotech industry and has contributed to developing a range of recombinant protein therapeutics, including monoclonal antibodies and antibody-drug conjugates. Kathy was a member of the Casss board of directors and was instrumental in establishing the annual Cell & Gene Therapy Products (CGTP) conference. She joined Genentech in 1997 as a Scientist in Analytical Chemistry where she led a proteomics research effort that established the company’s multi-product host cell protein assays. Since then, she has held various roles, including Executive Director of CMC Regulatory, Director of Protein Analytical Chemistry, and Senior Scientist in Analytical Development. In addition to her functional leadership roles, Kathy has led a variety of cross-functional teams, including a CMC team responsible for post-approval process changes and manufacturing site transfers for one of the company’s largest products. Prior to joining Genentech, Kathy was a Visiting Scientist at the Max Planck Institute for Marine Microbiology in Germany.